Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 20, 2017
The US subsidiary of Dr. Reddy’s has reached a settlement with the US Government involving packaging for five blister-packed prescription products.
read more
Dr. Reddy’s announced the launch of Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets, USP.
read more
Monday, February 01, 2016
Dr. Reddy's Laboratories has announcedthat the U.S. Food and Drug Administration tentative approval for Zenavod™ (doxycycline) Capsules, 40 mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and...
read more
Dr. Reddy's Laboratories and XenoPort have entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical ...
read more
Wednesday, October 23, 2019
Dr. Reddy’s confirms it initiated a voluntary nationwide recall of all of its ranitidine medications sold in US due to confirmed contamination with NDMA above levels established by the FDA.
read more
Dr. Reddy’s has entered into a purchase agreement with Upsher-Smith Laboratories, pursuant to which the company would sell its US and select territory rights for ZEMBRACE®, SYMTOUCH®, and TOSYMRA™.
read more
Dr. Reddy's Laboratories Limited and Integra LifeSciences Holdings Corporation have entered into an exclusive distribution agreement. Under the agreement, Dr. Reddy’s will market and distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration ...
read more
Dr. Reddy’s Laboratories has announced the acquisition of a portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN’S®, BUFFERIN®, ...
read more
Dr. Reddy’s and its subsidiary, Promius Pharma announced the filing of NDA for its migraine candidate DFN-02 with the FDA.
read more
Dr. Reddy’s announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL Single-dose Vials, the generic equivalent of Geodon.
read more
Monday, December 30, 2019
Dr. Reddy’s announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial, the therapeutic generic equivalent of Nitropress® Injection.
read more
Wednesday, October 10, 2018
Dr. Reddy’s Laboratories has launched Colesevelam HCl Tablets, USP, a therapeutic equivalent generic version of WELCHOL in the United States market approved by the FDA.
read more
Wednesday, November 28, 2018
Dr. Reddy’s announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the FDA.
read more
Wednesday, December 26, 2018
Dr. Reddy’s announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox, in the U.S. market from the FDA.
read more
Dr. Reddy’s Laboratories has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules in the United States market, having been ...
read more